Treatment of Congenital Long QT Syndrome Presenting with Syncope (Fainting) Before Medical Therapy

This protocol applies to patients with congenital long QT syndrome who have experienced syncope — fainting episodes — before any medical treatment has been started. This presentation is considered symptomatic LQTS and defines a specific clinical population requiring a structured first-line intervention.

Syncope (fainting) prior to medical treatment is a key risk marker in congenital LQTS. It identifies patients in whom the risk of arrhythmic events is sufficient to warrant both risk-reduction measures and pharmacological therapy.

Management combines general risk-reduction measures with a non-selective beta-blocker as the pharmacological backbone. In certain patients, the specific genotype may warrant an additional agent alongside the standard approach.

The complete regimen — including which genotype-specific options apply, the monitoring strategy, and the full prescribing algorithm — is available in the structured protocol.

In eligible patients receiving a specific add-on therapy, the key target is a meaningful shortening of the QTc interval on oral testing, confirmed before committing to long-term treatment.